Who owns Taysha Gene Therapies, Inc. (TSHA)? Elite investor 13F holders

2 tracked elite investors reported holding Taysha Gene Therapies, Inc as of 2026-06-30, including D.E. Shaw, Polen Capital Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
D.E. ShawTAYSHA GENE THERAPIES INCSHARE2026-06-302026-08-14 00:00:0029954821.00 USD4398652.000000SharesreduceOriginal filing
Polen Capital ManagementTAYSHA GENE THERAPIES INCSHARE2026-06-302026-08-04 00:00:003331581.00 USD489219.000000SharesaddOriginal filing
Renaissance Technologies LLCTAYSHA GENE THERAPIES INCSHARE2026-06-302026-08-13 00:00:000.00 USD0.000000SharesexitedOriginal filing
Tudor InvestmentTAYSHA GENE THERAPIES INCSHARE2026-06-302026-08-14 00:00:000.00 USD0.000000SharesexitedOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown